Printer Friendly

Bone Morphogenetic Protein Market to Grow With a CAGR 3.1% by 2023, Research and Markets Forecasts.

M2 PHARMA-June 1, 2017-Bone Morphogenetic Protein Market to Grow With a CAGR 3.1% by 2023, Research and Markets Forecasts

(C)2017 M2 COMMUNICATIONS

- The bone morphogenetic proteins market is growing at a fast pace due to the rise in sports and road accidents injuries, according to a report from Dublin-based Research and Markets.

A rising number of people who are suffering from spinal injuries together with a rise in surgical rates are primary drivers for the market.

According to the National spinal cord injury statistical center, approx 314m people in the US suffered from spinal cord injuries in 2016.

The global bone morphogenetic protein market has enormous opportunity to increase its demand in emerging countries.

The major challenge is the lack of professionals in the field of bone morphogenetic protein market, hampering the BMP market growth. The global bone morphogenetic proteins market is segmented on the basis of type and application.

On the basis of type, the global bone morphogenetic protein market is sub divided into recombinant bone morphogenetic protein-7 (rhBMP-7) and recombinant bone morphogenetic protein-2 (rhBMP-2).

On the basis of application, the bone morphogenetic proteins market is sub divided into oral maxillofacial surgery, spinal fusion, reconstructive and trauma.

Spinal fusion segment shows the largest market share globally due to various factors such as increasing demand for minimally invasive medical procedures, rise in sports injuries, rise in spinal injuries and the growing geriatric population etc.

Key players in this market include Allosource, Baxter International, Depuy Synthes, Integra Lifesciences Holdings Corp., Johnson and Johnson, Medtronic Plc, Musculoskeletal Transplant Foundation, Nuvasive, Inc., Orthofix Holdings, Inc, Smith and Nephew, Inc., Stryker Corp., Wright Medical Group N.V., Xtant Medical Holdings, Inc and Zimmer Biomet Holdings, Inc.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 1, 2017
Words:295
Previous Article:vTv Therapeutics Completes Enrollment of Part B of Pivotal Phase III STEADFAST Trial.
Next Article:Kadmon Touts Data Demonstrating the Potential of Its New GLUT Inhibitors for the Treatment of Autoimmune and Inflammatory Conditions.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters